Abiopharma

Clinical trial NCT03135886 updates: 1. completion date: 2026-07-31 → 2026-08-31 2. primary completion date: 2026-01-31 → 2026-08-31

Clinical trial NCT06854042 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. completion date: 2025-12-23 → 2027-07-22 3. primary completion date: 2025-12-23 → 2027-07-22

Clinical trial NCT07235046: enrollment: 233 → 234 participants.

General Announcement: ANNOUNCEMENT ON RECEIPT OF DRUG REGISTRATION CERTIFICATE BY XINXIN PHARMACEUTICAL PLANT

GCL Announces Adjournment of Extraordinary General Meeting to December 1, 2026

Net Asset Value(s)

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Edible Garden Schedules Q2 2026 Financial Results and Business Update Conference Call

Sidus Space to Host Second Quarter Financial Results Conference Call on August 14 at 5:00 p.m. ET